Fig. 2: Manhattan plots for fatigue in the EORTC QLQ-C30 (N = 1147) and distinct fatigue dimensions in the Multidimensional Fatigue Inventory (up to N = 677) up to two years following external beam radiotherapy in prostate cancer patients of the REQUITE cohort without fatigue before the start of radiotherapy. | Nature Communications

Fig. 2: Manhattan plots for fatigue in the EORTC QLQ-C30 (N = 1147) and distinct fatigue dimensions in the Multidimensional Fatigue Inventory (up to N = 677) up to two years following external beam radiotherapy in prostate cancer patients of the REQUITE cohort without fatigue before the start of radiotherapy.

From: Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients

Fig. 2: Manhattan plots for fatigue in the EORTC QLQ-C30 (N = 1147) and distinct fatigue dimensions in the Multidimensional Fatigue Inventory (up to N = 677) up to two years following external beam radiotherapy in prostate cancer patients of the REQUITE cohort without fatigue before the start of radiotherapy.The alternative text for this image may have been generated using AI.

Multivariable regression models were adjusted for age and BMI at enrolment, depression, hormone therapy, prostatectomy, tumour size, nodal involvement, pelvic radiotherapy, and the top 5 principal components. The red line indicates genome-wide statistical significance (P < 5 × 10−8) and the blue line indicates suggestive significance (P < 5 × 10−6). Source data are provided as a Source Data file.

Back to article page